Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. Timmer, E. Massana, E. Jiménez, B. Seoane, G. de Miquel, S. Ruiz (Mannheim, Germany; Barcelona, Spain). LAS100977, a novel, selective, long-acting β₂-agonist, improves airway conductance and reduces airway resistance in healthy subjects. Eur Respir J 2010; 36: Suppl. 54, 1188

Member's Comments

No comment yet.

Related content which might interest you: Use of continuous positive airway pressure reduces airway reactivity in adults with asthma Source: Eur Respir J 2013; 41: 317-322 Year: 2013 PUR1800 (RV1162), A novel narrow spectrum kinase inhibitor, but not Fluticasone, reduces TNFa-induced cytokine release by primary bronchial epithelial cells from healthy volunteers and COPD patients Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018 Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD Source: Eur Respir J 2003 Dec 01;22(6):926-930 Year: 2003 Airway resistance variability and response to bronchodilator in children with asthma Source: Eur Respir J 2007; 30: 260-268 Year: 2007 Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004 How should airways resistance be measured in young children: mask or mouthpiece? Source: Eur Respir J 2001; 17: 1244-1249 Year: 2001 Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Source: Eur Respir J 2002; 20: 1080-1087 Year: 2002 Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease: results of a 6-month trial Source: Eur Respir J 2001; 18: Suppl. 33, 94s Year: 2001 Pharmacological characterisation of indacaterol (QAB149), a novel once-daily inhaled β2-agonist, on small airways in human and rat lung slices Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006 Can we use drugs to modulate upper airway function in OSA? Source: International Congress 2018 – Sleep apnoea: is it time for new therapies? Year: 2018 Effect of dual bronchodilation with indacaterol/glycopirronium on small airways resistance in patients with stable COPD Source: International Congress 2016 – Non-inflammatory COPD monitoring Year: 2016 Formoterol protects against platelet-activating factor-induced effects in asthma Source: Eur Respir J 2004; 23: 71-75 Year: 2004 Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2-agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003 RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Plethysmographic measurements of lung volume and airway resistance Source: Eur Respir J 2001; 17: 302-312 Year: 2001 The effects of body weight on airway calibre Source: Eur Respir J 2005; 25: 896-901 Year: 2005 Inhaled corticosteroids and growth of airway function in asthmatic children Source: Eur Respir J 2004; 23: 861-868 Year: 2004 Airway calibre variability by forced oscillation technique: a sensitive indicator of bronchodilator effect in asthmatic children Source: Annual Congress 2005 - Monitoring paediatric asthma Year: 2005 Dose response of continuous positive airway pressure on nasal symptoms, obstruction and inflammation in vivo and in vitro Source: Eur Respir J 2012; 40: 1180-1190 Year: 2012 Initiating oral breathing in response to nasal loading: asthmatics versus healthy subjects Source: Eur Respir J 2008; 31: 800-806 Year: 2008